HeyJaredDarren Incorvaia
- Indexed articles, last 90 days
- 7
- Latest publication
- Oct 1, 2026
- Outlet visibility, for FierceBiotech
- Top 500K sites
- Earliest in this view
- Sep 24, 2026
Latest articles
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken (opens the original)
Read excerpt
The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to dispel worries about broader implications for the drug mechanism involved. A May protocol amendment for European sites in the Aloft program describes multiple cases of liver toxicity, including a patient who died after “multi-organ failure involving acute hepatic injury.” “Most events were mild, transien
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future (opens the original)
Read excerpt
When recombinant DNA expert Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time. “He said, ‘I'll meet you for 10 minutes.’ He had to be convinced to meet,” Ashley Magargee, now CEO of the pioneering biopharma organization that Boyer and Swanson founded, told Fierce on a recent tour of Genentech’s headquarters. “They met in this bar called Churchill's, and three hours later they h
Beam Therapeutics sues base editing rival, claims former scientist stole secrets (opens the original)
Read excerpt
Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets behind one of its lead programs and used them to craft a competing therapy. The allegations center on Zi Jun (Emma) Wang, Ph.D., whom the suit says was employed at Beam as a scientist from March 2021 to January 31, 2022. While working at the company, in July 2021, Beam claims Wang secretly founded a Chinese startup—YolTech Therapeutics—to pursue a base editing therapy for
Enanta sheds staffers as key antiviral, immunology readouts loom (opens the original)
Read excerpt
As antiviral specialist Enanta Pharmaceuticals endeavors to expand into immunology, the company has decided to lay off 37 employees, Fierce has learned. “As we approached our fiscal year end, we conducted a careful evaluation of the resources and capabilities needed to execute against our current priorities,” the company told Fierce in a statement. “As a result, we made the difficult decision to right-size the company across all departments to operate more efficiently.” Based in Watertown, Massa
Roche drops muscle-sparing obesity antibody after flunked interim analysis (opens the original)
Read excerpt
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study. The Swiss pharma has handed emugrobart back to its Japanese subsidiary Chugai, which will resume development of the molecule for a rare genetic disease while also seeking potential partners. Emugrobart is meant to block the activity of myostatin, a protein that acts as a check on muscle growth. By inhibiting myostatin and pairing with a GLP-1 like Lilly’s tirzep
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For FierceBiotech, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.